Terms: = Liver cancer AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E AND Treatment
31 results:
1. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Narayan R; Piérola AA; Donnellan WB; Yordi AM; Abdul-Hay M; Platzbecker U; Subklewe M; Kadia TM; Alonso-Domínguez JM; McCloskey J; Bradford K; Curtis M; Daskalakis N; Guttke C; Safer K; Hiebert B; Murphy J; Li X; Duchin K; Esteban D
Clin Transl Sci; 2024 Mar; 17(3):e13742. PubMed ID: 38494922
[TBL] [Abstract] [Full Text] [Related]
2. Prediction of proton stopping power ratios using dual-energy CT basis material decomposition.
Pettersson E; Thilander-Klang A; Bäck A
Med Phys; 2024 Feb; 51(2):881-897. PubMed ID: 38194501
[TBL] [Abstract] [Full Text] [Related]
3. Repurposing of Strychnine as the Potential Inhibitors of Aldo-keto Reductase Family 1 Members B1 and B10: Computational Modeling and Pharmacokinetic Analysis.
Sarfraz M; Aziz M; Afzal S; Channar PA; Alsfouk BA; Kandhro GA; Hassan S; Sultan A; Hamad A; Arafat M; Qaiser MN; Ahmed A; Siddique F; Ejaz SA
Protein J; 2024 Apr; 43(2):207-224. PubMed ID: 37940790
[TBL] [Abstract] [Full Text] [Related]
4. Androgen use in bone marrow failures and myeloid neoplasms: Mechanisms of action and a systematic review of clinical data.
Bosi A; Barcellini W; Passamonti F; Fattizzo B
Blood Rev; 2023 Nov; 62():101132. PubMed ID: 37709654
[TBL] [Abstract] [Full Text] [Related]
5. Cytidine deaminase status as a marker of response to azacytidine treatment in mds and AML patients.
Donnette M; Hamimed M; Ciccolini J; Sicard G; Correard F; Farnault L; Ouafik L; Venton G; Fanciullino R
Br J Haematol; 2023 Nov; 203(4):625-636. PubMed ID: 37691342
[TBL] [Abstract] [Full Text] [Related]
6. In silico design of novel CDK2 inhibitors through QSAR, ADMET, molecular docking and molecular dynamics simulation studies.
Moussaoui M; Baassi M; Baammi S; Soufi H; Salah M; Daoud R; El Allali A; Belghiti ME; Belaaouad S
J Biomol Struct Dyn; 2023; 41(23):13646-13662. PubMed ID: 37203327
[TBL] [Abstract] [Full Text] [Related]
7. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.
Bose P; McCue D; Wurster S; Wiederhold NP; Konopleva M; Kadia TM; Borthakur G; Ravandi F; Masarova L; Takahashi K; Estrov Z; Yilmaz M; Daver N; Pemmaraju N; Naqvi K; Rausch CR; Marx KR; Qiao W; Huang X; Bivins CA; Pierce SA; Kantarjian HM; Kontoyiannis DP
Clin Infect Dis; 2021 May; 72(10):1755-1763. PubMed ID: 32236406
[TBL] [Abstract] [Full Text] [Related]
8. Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model.
Ramsey HE; Oganesian A; Gorska AE; Fuller L; Arrate M; Boyd K; Keer H; Azab M; Savona MR
Target Oncol; 2020 Apr; 15(2):231-240. PubMed ID: 32222953
[TBL] [Abstract] [Full Text] [Related]
9. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
Angelucci E; Li J; Greenberg P; Wu D; Hou M; Montano Figueroa EH; Rodriguez MG; Dong X; Ghosh J; Izquierdo M; Garcia-Manero G;
Ann Intern Med; 2020 Apr; 172(8):513-522. PubMed ID: 32203980
[TBL] [Abstract] [Full Text] [Related]
10. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.
Goncalves I; Burbury K; Michael M; Iravani A; Ravi Kumar AS; Akhurst T; Tiong IS; Blombery P; Hofman MS; Westerman D; Hicks RJ; Kong G
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1902-1910. PubMed ID: 31187162
[TBL] [Abstract] [Full Text] [Related]
11. Severe Deoxyguanosine Kinase Deficiency in Austria: A 6-Patient Series.
Waich S; Roscher A; Brunner-Krainz M; Cortina G; Köstl G; Feichtinger RG; Entenmann A; Müller T; Knisely AS; Mayr JA; Janecke AR; Vodopiutz J
J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):e1-e6. PubMed ID: 30589726
[TBL] [Abstract] [Full Text] [Related]
12. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
Kattamis A; Aydinok Y; Taher A
Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
[TBL] [Abstract] [Full Text] [Related]
13. A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.
Verschoor AJ; Warmerdam FARM; Bosse T; Bovée JVMG; Gelderblom H
BMC Cancer; 2018 Jan; 18(1):92. PubMed ID: 29357824
[TBL] [Abstract] [Full Text] [Related]
14. Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 23 Cases.
Wu B; Ingersoll K; Jug R; Yang LH; Luedke C; Lo A; Su P; Liu X; Rehder C; Gong J; Lu CM; Wang E
Am J Clin Pathol; 2017 Dec; 149(1):55-66. PubMed ID: 29228125
[TBL] [Abstract] [Full Text] [Related]
15. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
Imran F; Phatak P
Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
[TBL] [Abstract] [Full Text] [Related]
16. Good riddance to the term "refractory anemia" in myelodysplastic syndromes.
Steensma DP
Leuk Res; 2016 Dec; 51():22-26. PubMed ID: 27776290
[TBL] [Abstract] [Full Text] [Related]
17. Radiotherapy- and chemotherapy-induced myelodysplasia syndrome: a nationwide population-based nested case-control study.
Sun LM; Lin CL; Lin MC; Liang JA; Kao CH
Medicine (Baltimore); 2015 May; 94(17):e737. PubMed ID: 25929909
[TBL] [Abstract] [Full Text] [Related]
18. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.
Chang TY; Dvorak CC; Loh ML
Blood; 2014 Oct; 124(16):2487-97. PubMed ID: 25163700
[TBL] [Abstract] [Full Text] [Related]
19. Acute myeloid leukemia following solid organ transplantation: case report and comprehensive review.
Kourelis TV; Boruchov A; Hull D; Polio J; Scholes J; Moustakakis M; Bilgrami SF
Conn Med; 2012 Mar; 76(3):151-4. PubMed ID: 22666974
[TBL] [Abstract] [Full Text] [Related]
20. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia.
Loh ML
Br J Haematol; 2011 Mar; 152(6):677-87. PubMed ID: 21623760
[TBL] [Abstract] [Full Text] [Related]
[Next]
